Bard Financial Services, Inc. Ionis Pharmaceuticals Inc Transaction History

Bard Financial Services, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$42.03 - $53.55 $174,424 - $222,232	-4,150 Reduced 29.43%	9,950 $431,000
Q4 2023 Feb 09, 2024	SELL	$43.39 - $51.63 $496,815 - $591,163	-11,450 Reduced 44.81%	14,100 $713,000
Q3 2023 Oct 16, 2023	SELL	$38.5 - $47.13 $221,375 - $270,997	-5,750 Reduced 18.37%	25,550 $1.16 Million
Q2 2023 Jul 11, 2023	SELL	$34.73 - $43.33 $18,233 - $22,748	-525 Reduced 1.65%	31,300 $1.28 Million
Q1 2023 Apr 26, 2023	SELL	$33.58 - $41.2 $742,118 - $910,520	-22,100 Reduced 40.98%	31,825 $1.14 Million
Q4 2022 Jan 25, 2023	SELL	$37.12 - $46.52 $1.26 Million - $1.58 Million	-33,970 Reduced 38.65%	53,925 $2.04 Million
Q3 2022 Oct 26, 2022	SELL	$36.54 - $48.66 $202,797 - $270,063	-5,550 Reduced 5.94%	87,895 $3.89 Million
Q2 2022 Jul 06, 2022	SELL	$31.71 - $43.0 $176,783 - $239,725	-5,575 Reduced 5.63%	93,445 $3.46 Million
Q1 2022 Apr 13, 2022	BUY	$29.88 - $37.04 $1.72 Million - $2.13 Million	57,500 Added 138.49%	99,020 $3.67 Million
Q4 2021 Jan 24, 2022	BUY	$25.61 - $35.1 $814,269 - $1.12 Million	31,795 Added 326.94%	41,520 $1.26 Million
Q3 2021 Oct 15, 2021	BUY	$33.54 - $40.55 $326,176 - $394,348	9,725 New	9,725 $326,000

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Bard Financial Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Bard Financial Services, Inc. with notifications on news.